Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

RSS icon

CityMD agrees to $12M settlement over alleged COVID claims fraud

The company cooperated with a DoJ investigation into COVID-19 tests being erroneously billed to the federal government.

physician tracking patient data and reporting on outcomes

Q&A: Cardiologist Karen Joynt Maddox on why new healthcare policies are not improving outcomes

Healthcare's ongoing shift toward value-based care is a good thing, Joynt Maddox explained, but its implementation has been far from ideal. She also discussed population health, the pandemic, health disparities and the rising influence of private equity investments.

Drawing inspiration from the World War II “Why We Fight” campaign that rallied support for the U.S. war effort, American Medical Association (AMA) President Jesse M. Ehrenfeld, MD, MPH, drew comparisons with the uphill battles physicians are facing today with dwindling reimbursements, physicians shortages, burnout and administrative fights against prior authorization burdens and attempts to preserve access to telehealth. #AMA #AMAHOD24 #AMAHOD2024 #HOD #HOD24 #HOD2024

AMA president calls for physicians to take war-time footing in fight over reimbursement, care quality

Drawing inspiration from the World War II “Why We Fight” campaign that rallied support for the U.S. war effort, AMA President Jesse  Ehrenfeld, MD, spoke on the uphill battles physicians are facing today.

healthcare money economics dollar stethoscope acquire merger

California bill: Private equity firms must seek AG approval for healthcare buyouts

California Assembly bill AB-3129 requires private equity investors to send an application to the state attorney general 90 days before they purchase a hospital or provider group.

FDA panel recommends new COVID-19 booster

Booster uptake rates remain low. To date, only 22.5% of Americans received an annual COVID-19 shot from 2023.

Moon Surgical gets FDA approval for mission launch of surgery robot

The Maestro robot aids surgeons by holding tools and providing real-time analysis of a surgery.

FDA announces recall of Medtronic brain surgery support systems

Medtronic has issued a recall affecting several versions of its StealthStation S8 due to a software error that puts patients at risk of serious injury or death.

Heart Rhythm Society (HRS) President Kenneth Ellenbogen, MD, FHRS, director of clinical cardiac electrophysiology and pacing, Virginia Commonwealth University, discussed two key initiatives for 2024-25 with Cardiovascular Business. These include helping create a new, independent cardiovascular medicine board, and supporting the movement toward more outpatient procedures being performed in office-based labs (OBL) and ambulatory surgical centers (ASC). #EPeeps #HRS #HRS24 #HRS2024

Heart Rhythm Society shows support for new cardiovascular board, outpatient EP centers

Cardiovascular Business spoke with HRS President Kenneth Ellenbogen, MD, about two key initiatives the group is focused on this year.

Displaying 161 - 168 of 2769

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup